Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 8, 2015, Pages F910-F922

  Wang, Weidong ^a   Luo, Renfei ^a   Lin, Yu ^a   Wang, Feifei ^a   Zheng, Peili ^a   Levi, Moshe ^b   Yang, Tianxin ^a,c   Li, Chunling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaporin 2; Obstructive nephropathy; Renin inhibition; Water channel

Indexed keywords

ALISKIREN; AQUAPORIN 2; CREATININE; CRYOPYRIN; ENALAPRIL; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; VASOPRESSIN V2 RECEPTOR; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AQP2 PROTEIN, MOUSE; AQP2 PROTEIN, RAT; AUTACOID; CARRIER PROTEIN; CELL RECEPTOR; CIAS1 PROTEIN, MOUSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE; NOD-LIKE RECEPTOR 3, RAT; RENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SERUM OSMOLALITY; URETER OBSTRUCTION; URINE OSMOLALITY; URINE VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL PROTECTION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; KIDNEY; KIDNEY DISEASES; METABOLISM; TIME; UPREGULATION; URETERAL OBSTRUCTION; WISTAR RAT;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AQUAPORIN 2; CARRIER PROTEINS; CELLS, CULTURED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FUMARATES; INFLAMMASOMES; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY DISEASES; MALE; MICE, INBRED C57BL; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; URETERAL OBSTRUCTION;

EID: 84927709540     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00649.2014     Document Type: Article

References (53)

1. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 22: 1007–1018, 2011.
2. Andersen JH, Boesen HC, Skovgaard Olsen K. Sleep in the Intensive Care Unit measured by polysomnography. Minerva Anestesiol 79: 804–815, 2013.
3. Bansal AD, Hoffert JD, Pisitkun T, Hwang S, Chou CL, Boja ES, Wang G, Knepper MA. Phosphoproteomic profiling reveals vasopressinregulated phosphorylation sites in collecting duct. J Am Soc Nephrol 21: 303–315, 2010.
4. Boesen EI. Chronic elevation of IL-1+ induces diuresis via a cyclooxygenase 2-mediated mechanism. Am J Physiol Renal Physiol 305: F189–F198, 2013.
5. Boesen EI, Sasser JM, Saleh MA, Potter WA, Woods M, Warner TD, Pollock JS, Pollock DM. Interleukin-1+, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol 295: F446–F453, 2008.
6. Braam B, Mitchell KD, Fox J, Navar LG. Proximal tubular secretion of angiotensin II in rats. Am J Physiol Renal Fluid Electrolyte Physiol 264: F891–F898, 1993.
7. Chagnon F, Vaidya VS, Plante GE, Bonventre JV, Bernard A, Guindi C, Lesur O. Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Crit Care Med 36: 3054–3061, 2008.
8. Choi DE, Jeong JY, Lim BJ, Chang YK, Na KR, Shin YT, Lee KW. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. J Urol 186: 694–701, 2011.
9. Christensen BM, Wang W, Frokiaer J, Nielsen S. Axial heterogeneity in basolateral AQP2 localization in rat kidney: effect of vasopressin. Am J Physiol Renal Physiol 284: F701–F717, 2003.
10. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29: 707–735, 2011.
11. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415–472, 2000.
12. De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal renin-angiotensin systems. Front Endocrinol 5: 16, 2014.
13. Feldman DL, Jin L, Xuan H, Persohn E, Zhou W, Schuetz H, Park JK, Muller DN, Luft FC. The direct renin inhibitor aliskiren localizes and persists in rat kidneys. Am J Physiol Renal Physiol 305: F1593–F1602, 2013.
14. Frokiaer J, Djurhuus JC, Nielsen M, Pedersen EB. Renal hemodynamic response to ureteral obstruction during converting enzyme inhibition. Urol Res 24: 217–227, 1996.
15. Frokiaer J, Knudsen L, Nielsen AS, Pedersen EB, Djurhuus JC. Enhanced intrarenal angiotensin II generation in response to obstruction of the pig ureter. Am J Physiol Renal Fluid Electrolyte Physiol 263: F527–F533, 1992.
16. Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G. Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 65: 54–62, 2004.
17. Hammad FT, Al-Salam S, Lubbad L. Does aliskiren protect the kidney following ischemia reperfusion injury? Physiol Res 6: 681–690, 2013.
18. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285–1294, 1995.
19. Jensen AM, Bae EH, Fenton RA, Norregaard R, Nielsen S, Kim SW, Frokiaer J. Angiotensin II regulates V2 receptor and pAQP2 during ureteral obstruction. Am J Physiol Renal Physiol 296: F127–F134, 2009.
20. Jensen AM, Li C, Praetorius HA, Norregaard R, Frische S, Knepper MA, Nielsen S, Frokiaer J. Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. Am J Physiol Renal Physiol 291: F1021–F1032, 2006.
21. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 45: 1637–1647, 1994.
22. Kang YS, Lee MH, Song HK, Hyun YY, Cha JJ, Ko GJ, Kim SH, Lee JE, Han JY, Cha DR. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 4: 1194–1204, 2011.
23. Kedrah AE, Ari E, Alahdab Y, Gul CB, Macunluoglu B, Atakan A, Asicioglu E, Cakalagaoglu F, Koc M. Effect of the direct renin inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat. Kidney Blood Press Res 35: 425–430, 2012.
24. Kellner D, Chen J, Richardson I, Seshan SV, El Chaar M, Vaughan ED Jr, Poppas D, Felsen D. Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. J Urol 176: 806–812, 2006.
25. Komada T, Usui F, Shirasuna K, Kawashima A, Kimura H, Karasawa T, Nishimura S, Sagara J, Noda T, Taniguchi S, Muto S, Nagata D, Kusano E, Takahashi M. ASC in renal collecting duct epithelial cells contributes to inflammation and injury after unilateral ureteral obstruction. Am J Pathol 184: 1287–1298, 2014.
26. Kwon TH, Nielsen J, Knepper MA, Frokiaer J, Nielsen S. Angiotensin II AT1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats. Am J Physiol Renal Physiol 288: F673–F684, 2005.
27. Lech M, Weidenbusch M, Kulkarni OP, Ryu M, Darisipudi MN, Susanti HE, Mittruecker HW, Mak TW, Anders HJ. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol 22: 1443–1452, 2011.
28. Li C, Klein JD, Wang W, Knepper MA, Nielsen S, Sands JM, Frokiaer J. Altered expression of urea transporters in response to ureteral obstruction. Am J Physiol Renal Physiol 286: F1154–F1162, 2004.
29. Li C, Wang W, Kwon TH, Isikay L, Wen JG, Marples D, Djurhuus JC, Stockwell A, Knepper MA, Nielsen S, Frokiaer J. Downregulation of AQP1, -2, and -3 after ureteral obstruction is associated with a long-term urine-concentrating defect. Am J Physiol Renal Physiol 281: F163–F171, 2001.
30. Li C, Wang W, Kwon TH, Knepper MA, Nielsen S, Frokiaer J. Altered expression of major renal Na transporters in rats with bilateral ureteral obstruction and release of obstruction. Am J Physiol Renal Physiol 285: F889–F901, 2003.
31. Li C, Wang W, Kwon TH, Knepper MA, Nielsen S, Frokiaer J. Altered expression of major renal Na transporters in rats with unilateral ureteral obstruction. Am J Physiol Renal Physiol 284: F155–F166, 2003.
32. Li C, Wang W, Rivard CJ, Lanaspa MA, Summer S, Schrier RW. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am J Physiol Renal Physiol 300: F1255–F1261, 2011.
33. Li C, Wang W, Summer SN, Cadnapaphornchai MA, Falk S, Umenishi F, Schrier RW. Hyperosmolality in vivo upregulates aquaporin 2 water channel and Na-K-2Cl co-transporter in Brattleboro rats. J Am Soc Nephrol 17: 1657–1664, 2006.
34. Ma T, Song Y, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc Natl Acad Sci USA 97: 4386–4391, 2000.
35. Magaldi AJCK, de Araújo M, Simões e Silva AC, Santos RA. Angiotensin-(1–7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflügers Arch 447: 223–230, 2003.
36. Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 90: 11663–11667, 1993.
37. Olesen ET, de Seigneux S, Wang G, Lutken SC, Frokiaer J, Kwon TH, Nielsen S. Rapid and segmental specific dysregulation of AQP2, S256- pAQP2 and renal sodium transporters in rats with LPS-induced endotoxaemia. Nephrol Dial Transplant 24: 2338–2349, 2009.
38. Ostergaard M, Christensen M, Nilsson L, Carlsen I, Frokiaer J, Norregaard R. ROS dependence of cyclooxygenase-2 induction in rats subjected to unilateral ureteral obstruction. Am J Physiol Renal Physiol 306: F259–F270, 2014.
39. Rashikh A, Pillai KK, Ahmad SJ, Akhtar M, Najmi AK. Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin Angiotensin Aldosterone Syst 14: 14–22, 2013.
40. Reams G, Villarreal D, Wu Z, Bauer JH. Renal tissue angiotensin II: response to infusions of angiotensin I and an angiotensin-converting enzyme inhibitor. Am J Kidney Dis 22: 851–857, 1993.
41. Reilly AM, Harris PJ, Williams DA. Biphasic effect of angiotensin II on intracellular sodium concentration in rat proximal tubules. Am J Physiol Renal Fluid Electrolyte Physiol 269: F374–F380, 1995.
42. Sakuraya K, Endo A, Someya T, Hirano D, Murano Y, Fujinaga S, Ohtomo Y, Shimizu T. The synergistic effect of mizoribine and a direct renin inhibitor, aliskiren, on unilateral ureteral obstruction induced renal fibrosis in rats. J Urol 191: 1139–1146, 2014.
43. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 121: 265–271, 2008.
44. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. Long-term regulation of four renal aquaporins in rats. Am J Physiol Renal Fluid Electrolyte Physiol 271: F414–F422, 1996.
45. Topcu SO, Pedersen M, Norregaard R, Wang G, Knepper M, Djurhuus JC, Nielsen S, Jorgensen TM, Frokiaer J. Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. Am J Physiol Renal Physiol 292: F736–F748, 2007.
46. Versteilen AM, Heemskerk AE, Groeneveld AB, van Wijhe M, van Lambalgen AA, Tangelder GJ. Mechanisms of the urinary concentration defect and effect of desmopressin during endotoxemia in rats. Shock 2: 217–222, 2008.
47. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21: 1732–1744, 2010.
48. Wang W, Li C, Summer S, Falk S, Schrier RW. Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol Renal Physiol 299: F577–F584, 2010.
49. Wang W, Qiu L, Howard A, Solis N, Li C, Wang X, Kopp JB, Levi M. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 15: 384–395, 2014.
50. Wang Z, Liu Y, Han Y, Guan W, Kou X, Fu J, Yang D, Ren H, He D, Zhou L, Zeng C. Protective effects of aliskiren on ischemia-reperfusioninduced renal injury in rats. Eur J Pharmacol 718: 160–166, 2013.
51. Wong NL, Sonntag M, Tsui JK. Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an ETA/ETB receptor antagonist. Metabolism 52: 1141–1146, 2003.
52. Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 299: F929–F941, 2010.
53. Zhuo JL, Li XC. New insights and perspectives on intrarenal reninangiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 32: 1551–1565, 2011.